

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for September 2022

Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mantra Pharma Inc.	M-Valsartan	Diovan	VALSARTAN	80 mg	tablet	02524538
Mantra Pharma Inc.	M-Valsartan	Diovan	VALSARTAN	160 mg	tablet	02524546
Pharmascience Inc.	Pms-Deferasirox (Type J)	Jadenu	DEFERASIROX	90mg	tablet	02528290
Pharmascience Inc.	Pms-Deferasirox (Type J)	Jadenu	DEFERASIROX	360mg	tablet	02528312
Glenmark Pharmaceuticals Canada Inc.	GLN-Atovaquone	Mepron	ATOVAQUONE	750 mg/5mL	oral suspension	02528495

Pharmascience Inc.	Pmsc-Venlafaxine XR	Effexor XR	VENLAFAXINE HYDROCHLORIDE	75 mg	ER capsule	02521482
Pharmascience Inc.	Pmsc-Venlafaxine XR	Effexor XR	VENLAFAXINE HYDROCHLORIDE	150 mg	ER capsule	02521474
Mint Pharmaceuticals Inc.	Mint-Acyclovir	Zovirax	ACYCLOVIR	200 mg	tablet	02524708
Mint Pharmaceuticals Inc.	Mint-Acyclovir	Zovirax	ACYCLOVIR	400 mg	tablet	02524716
Mint Pharmaceuticals Inc.	Mint-Acyclovir	Zovirax	ACYCLOVIR	800 mg	tablet	02524724
Mint Pharmaceuticals Inc.	Mint-Emtricitabine/Tenofovir	Truvada	EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE	200 mg/300 mg	tablet	02521547